Among patients with CAD, 38 (76%) were on metformin, 32 (64%) were on sulphonyl urea, 17 (34%) were on DPP-4 inhibitors, 15 (30%) on SGLT-2 inhibitors, and four (8%) were on alpha-glucosidases inhibitors. The gene discussed is SLC5A2; the disease is coronary artery disorder.